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CONCLUSION: HRT is the most cost-effective option, followed
by bisphosphonates, for 50-year-old hypothetical females, but
some assumptions and limitations apply (including small sample
sizes for the calcitonin and raloxifene groups, and a likely selec-
tion bias in that bisphosphonate users are more likely to report
longer duration of glucocorticoid therapy). Because few guide-
lines included cost-effectiveness information, consideration of
these results may facilitate better management of glucocorticoid-
induced osteoporosis.
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OBJECTIVE: Abatacept is a new selective co-stimulation modu-
lator recently approved in Brazil for the treatment of patients
with moderately to severely active rheumatoid arthritis (RA) and
inadequate response to one or more disease-modifying anti-
rheumatic drugs (DMARDs). We estimated the cost-effectiveness
of Abatacept in patients with inadequate response to Methotr-
exate. METHODS: We developed a Markov simulation model to
depict progression of functional disability over time in patients
with moderately to severely active RA and inadequate response
to MTX. Functional disability was expressed in terms of the
Health Assessment Questionnaire Disability Index (HAQ-DI).
Patients were assumed to receive weekly pulse MTX alone or
weekly pulse MTX plus abatacept administered on days 1, 14,
and 29, and every 4 weeks thereafter. Costs with drug acquisi-
tion, administration and monitoring were considered. Estima-
tions used data from a Phase III clinical trial of abatacept in
patients with inadequate response to MTX (AIM) plus secondary
data sources. Cost-effectiveness of abatacept was expressed in
terms of the incremental cost (2006 Brazil R$) per quality-
adjusted life-year (QALY) gained versus MTX therapy alone;
lifetime horizons was employed in the analyses. Costs and health
effects were discounted at 3% annually. RESULTS: Over the
lifetime, abatacept therapy was estimated to yield an average of
1.61 additional QALYs per patient (vs. MTX alone) at a mean
incremental cost of R$146.095/QALY (US$83,483, US$1 =
R$1.75). CONCLUSION: Abatacept presented the best cost-
effectiveness ratio vis-à-vis etanercept, adalimumab, and
inﬂiximab, with its incremental costs of R$202.581/QALY,
R$189.100/QALY and R$236.479/QALY, respectively vs. Meth-
rotexate alone.
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OBJECTIVE: Rituximab is a monoclonal antibody with demon-
strated efﬁcacy (REFLEX trial) in rheumatoid arthritis patients
who responded inadequately to anti-TNF drugs (Cohen et al.
2006). The study assessed the total cost of rituximab therapy in
comparison with inﬂiximab, adalimumab, etanercept and abata-
cept under a private payer perspective in Brazil. A budget impact
analysis was performed. METHODS: This study assumed the
same efﬁcacy for all drugs, since there has not been any head-
to-head trial available until now, although indirect comparisons
show higher ACR response rates for rituximab. Direct annual
medical costs for biological drugs, IV administration, weekly
metotrexate (MTX) and routine exams were taken from a panel
of Brazilian rheumatologists. Base case dosages considered were:
rituximab (2 g every 8 months), abatacept (750 mg at weeks 0, 2,
4 and then every 4 weeks), inﬂiximab (4 mg/kg at weeks 0, 2, 6
and every 8 weeks), adalimumab (40 mg every other week) and
etanercept (50 mg every week). Local administration costs were
obtained from Scheinberg et al. 2005. Costs were reported in
2007 Brazilian Reais and discounted at a 5% rate in the BIA.
Therapies were evaluated using a 5-year horizon. In order to
assess uncertainty, one and two-way sensitivity analyses were
performed. RESULTS: In the base case scenario, rituximab
therapy resulted in a total annual cost of R$46,388 per patient.
Total annual costs per patient for the comparators were:
R$79,394 for inﬂiximab, R$90,831 for adalimumab, R$120,351
for etanercept and R$77,118 for abatacept. In the BIA, ritux-
imab therapy resulted in total savings of R$94,201,413 in 5 years
considering the population in the private health care system only.
Results were sensitive to dosage schedule (rituximab, inﬂiximab
and abatacept) and drug costs. CONCLUSION: Results of this
study suggest that therapy with rituximab is a dominant alterna-
tive for patients with rheumatoid arthritis in the Brazilian private
health care system.
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OBJECTIVE: To assess the direct and indirect economic conse-
quences of rheumatoid arthritis (RA) using real-world data.
METHODS: Medical Expenditure Panel Survey (MEPS) 2004
data was used to identify non-institutionalized U.S. persons with
RA. MEPS is a comprehensive survey of approximately 35,000
individuals consisting of detailed health care resource use expen-
ditures by payer, employment and income, insurance detail and
quality of life (QoL) information. These data are novel because
they are nationally representative, capture the elderly and their
expenditure better than managed care databases, and contain
direct and indirect costs and QoL measures in the same popula-
tion. Multiple linear and semi-log regressions were applied to
estimate the total annual health care expenditure and income
loss associated with RA. Covariates in expenditure equations
included demography, comorbidities and overall health status.
Semi-log regression for income rendered the distribution of
income symmetric. Covariates in the income equations included
demography, comorbidities, education, occupation and health
status. RESULTS: A total of 136 patients with RA were identiﬁed
in the data; 76% were women, and 56% were 41–64 years of
age. Total annual incremental expenditure associated with RA
was $4422 (P < 0.01) with adjusted R2 of 0.16 in the linear
regression and 0.41 in the semi-log regression. 14% of those
expenses were paid by the individual or their family, 28% by
Medicare, 39% by private insurance and 14% by Medicaid. As
expected, deterioration in overall health status increased health
care expenditures monotonically. In the income equation
(adjusted R2 = 0.39), persons with RA earned $3526 less annu-
ally (P = 0.03) than the mean income of $26,594 consistent with
the US Census Bureau, translating into a 13% decrease. Income
increased with education and with improved overall health
status. CONCLUSION: Even when controlling for other factors,
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